Filtrera efter Last updated date SelectEfterFöreFrom - To Date Slutdatum Denna vecka Den här månaden Förra veckan Förra månaden Category HumanCorporateVeterinaryHerbal Topic MedicinesCOVID-19PharmacovigilanceVaccinesReferralsPaediatricsRare diseasesRegulatory and procedural guidanceClinical trialsAdvanced therapiesData on medicinesCompliance and inspectionsInnovationMedicine shortagesResearch and developmentBiosimilarsSMEAntimicrobial resistanceCorporateGovernanceBrexitQuality of medicinesGeneric and hybrid medicinesEarly accessMedicines for use outside the EUFeesProduct informationScientific adviceMedical devicesMaximum residue limitMpoxBiologicalsScientific guidelinesVeterinary limited marketsCompassionate useCareersMedication errorPRIMEParallel distributionProcurement Diseases area Viral diseasesCancerImmune-system diseasesDiabetesNeurodegenerative diseasesCardiovascular diseasesHIV and AIDS Responsible body CHMP CVMP PRAC Management Board COMP PDCO CMDh HMPC CAT Patient safety information Patient safety Lämna detta fält tomt Filter Resultat (3827) Sort by Last update date (new to old)Last update date (old to new)A-ZZ-A Lämna detta fält tomt EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly 2 november 2021NewsHumanCOVID-19 Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 October 2021 29 oktober 2021NewsHumanCOVID-19PharmacovigilanceReferralsVaccines Regulatory update - EMA encourages companies to submit type I variations for 2021 in November 2021 29 oktober 2021NewsHumanVeterinary Repurposing of authorised medicines: pilot to support not-for-profit organisations and academia 28 oktober 2021NewsHumanRegulatory and procedural guidanceScientific advice Call for expressions of interest for civil society representatives to participate in work of EMA 27 oktober 2021NewsHumanPharmacovigilance EMA working on COVID-19 during closure on 1 and 2 November 2021 27 oktober 2021NewsHumanCorporateCOVID-19 Generating high-quality evidence from registry-based studies 26 oktober 2021NewsHumanRegulatory and procedural guidanceScientific guidelines Spikevax: EMA recommendation on booster 25 oktober 2021NewsHumanCOVID-19Vaccines COVID-19: EMA starts rolling review of molnupiravir 25 oktober 2021NewsHumanCOVID-19Medicines EMA starts evaluating use of COVID-19 vaccine Comirnaty in children aged 5 to 11 18 oktober 2021NewsHumanCOVID-19PaediatricsVaccines 1 … 55 56 57 58 59 Page 59 of 383 60 61 62 63 … 383
EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly 2 november 2021NewsHumanCOVID-19
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 October 2021 29 oktober 2021NewsHumanCOVID-19PharmacovigilanceReferralsVaccines
Regulatory update - EMA encourages companies to submit type I variations for 2021 in November 2021 29 oktober 2021NewsHumanVeterinary
Repurposing of authorised medicines: pilot to support not-for-profit organisations and academia 28 oktober 2021NewsHumanRegulatory and procedural guidanceScientific advice
Call for expressions of interest for civil society representatives to participate in work of EMA 27 oktober 2021NewsHumanPharmacovigilance
EMA working on COVID-19 during closure on 1 and 2 November 2021 27 oktober 2021NewsHumanCorporateCOVID-19
Generating high-quality evidence from registry-based studies 26 oktober 2021NewsHumanRegulatory and procedural guidanceScientific guidelines
EMA starts evaluating use of COVID-19 vaccine Comirnaty in children aged 5 to 11 18 oktober 2021NewsHumanCOVID-19PaediatricsVaccines